Dr Jeff Davies

Dr Jeff Davies

MA, MRCP, FRCPath, PhD
Centre: Haemato-Oncology
Reader in Haemato-Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


My clinical and research interests are allogeneic haematopoietic stem cell transplantation (HSCT); graft-versus-host disease (GvHD)/graft-versus-tumour (GvT) effects; and adoptive immunotherapy.

Research Details

In the lab I focus on the development of novel approaches to improve efficacy and reduce toxicity of allogeneic HSCT and adoptive immunotherapy as treatments for blood cancers and other diseases.

Current funded research projects include pharmacological modulation of immune responses after allogeneic HSCT, genetic manipulation of donor cells to externally control their phenotype and examination of the metabolic pathways that trigger gastro-intestinal GvHD.

I now combine my laboratory and translational research programme with clinical practice with the Cancer Centre at Barts Health, with specific emphasis on the lymphoma service and development of the allogeneic transplant/immunotherapy programmes.

Profile

I developed my research interest during my MRC Clinical Research Training Fellowship at the Royal Free Hospital, London, where I studied ways to selectively deplete alloreactive donor T cells to reduce GvHD but maintain immune reconstitution after allogeneic HSCT. I was awarded the George Santos Award by the American Society for Blood and Marrow Transplantation for the best clinical research by a young investigator for this research.

In 2006, I joined the Dana-Farber Cancer Institute/Harvard Medical School as a junior faculty member in Medical Oncology. I performed translational research with Profs Lee Nadler and Eva Guinan using costimulatory blockade to induce allospecific anergy in donor lymphocytes, to reduce GvHD but preserve immune reconstitution and GvL effects after allogeneic HSCT.

During that time I also gained experience in other adoptive immunotherapy approaches to cancer treatment, and I was the recipient of a Career Development Award from the Leukaemia and Lymphoma Society and a New Investigator Award from the American Society for Blood and Marrow Transplantation.

In 2010 I joined the Centre for Haemato-Oncology in the Barts Cancer Institute as a Clinical Senior Lecturer funded initially as a Clinician Scientist by the MRC.

Qualifications

  • MA (Oxon) Physiological Sciences First Class 1989
  • BM BCh (Hons) (Oxon) 1992
  • MRCP (UK) 1996
  • MRCPath 2002
  • PhD (University of London) 2005
  • FRCPath 2008 

Funding

As principal investigator:

2018-2021 CRUK Clinical Research Fellowship

Exploiting metabolic reprogramming in human allogeneic T cell responses
(Total £230,000)

2018-2021 Campbell-Savours Fund

Integrated polyfunctional assessment of donor T-cell reconstitution after allogeneic haematopoietic stem cell transplantation to identify predictors of GvHD and GvT effects
(Total £85,000)

2018-2022 Leuka/Anthony Nolan/NHSBT

IMPACT Centre Award for clinical trials in transplantation
(Total £167,000)

2017-2020 CRUK Clinical Research Fellowship

Using autoimmunity as a guide to improve cancer immunotherapy
(Total £230,000)

2017-2018 Greg Wolf Foundation

Integrated polyfunctional assessment of donor T-cell reconstitution after allogeneic haematopoietic stem cell transplantation to identify predictors of GvHD and GvT effects
(Total £12,000)

2017-2020 William Harvey Research Limited

Identifying Mechanisms of Immune Escape that leads to Relapse of Acute Myeloid Leukaemia after Allogeneic Stem Cell Transplantation
(Total £300,000)

2015 - Bloodwise (formerly Leukaemia-Lymphoma Research) Project Grant ‘Defining the role of the Retinoic Acid Pathway in human gastro-intestinal GvHD
(Total £187,000)
2015 - Barts Charity

Clinical Research Fellowship: "Integrated polyfunctional assessment of donor T-cell reconstitution after allogeneic haematopoietic stem cell transplantation to identify predictors of Graft-versus-Host Disease and Graft-versus-Tumour effects"
(Total £132,260)

2014 - MRC

Clinical Research Fellowship: "Modulating human alloresponses with lenalidomide to improve the outcome of allogeneic haematopoietic stem cell transplantation"
(Total £230,000)

2014 - Barts Charity

Small Project grant: "Creating human donor T cells with conditional FOXP3 expression to improve control of alloreactivity after allogeneic haematopoietic stem cell transplantation"
(£6090)

Key Publications

Davies JK, L.L. Brennan, J.R. Wingard, C.R. Cogle, N. Kapoor, A. Shah, B.R. Dey, T.R. Spitzer, M. de Lima, L.J. Cooper, P.F. Thall, R. E Champlin, L.M. Nadler, E.C. Guinan Infusion of alloanergized donor lymphocytes after CD34-selected haploidentical myeloablative hematopoietic stem cell transplantation. Clin Cancer Res. (2018) [Epub ahead of print]. PMID: 29769208

Davies JK, Hassan S, Sarker S, , Besley C, Oakervee H, Smith M, Taussig D, Gribben JG and Cavenagh JD. Durable graft-versus-leukaemia effects without donor lymphocyte infusions- results of a Phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia Br J Haematol. (2018) 180(3):346-355. PMID: 29076145

E Kotsiou, J Okosun, C Besley, S Iqbal, J Matthews, J Fitzgibbon, JG Gribben, JK Davies. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood (2016). 7;128(1):72-81. PMID: 27103745

Kotsiou E, Gribben JG, Davies JK. Allospecific Tregs expanded after anergization remain suppressive in inflammatory conditions but lack expression of gut-homing molecules. Molecular Therapy (2016). [Epub ahead of print] PMID: 27049761

CM Barbon*, JK Davies*, A Voskertchian, RH Kelner, L. Brennan, LM Nadler, EC Guinan. CD8+ Suppressor T Cells Contribute to Alloantigen-specific Immune Tolerance After Alloanergization. American Journal of Transplantation (2014) 14(2):305-18. PMID: 24410845
* Joint first authorship

Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin R, Nadler LM, Guinan EC, and Cooper LJ. Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies. Cancer Research (2010) 70(10):3915-24. PMID: 20424114


Further Publications

For additional publications, please click here.


My clinical and research interests are allogeneic haematopoietic stem cell transplantation (HSCT); graft-versus-host disease (GvHD)/graft-versus-tumour (GvT) effects; and adoptive immunotherapy.

External Activities

  • British Society for Blood and Marrow Transplantation member
  • National Steering Committee Chair HLA-epitope matching and platelet transfusion study
  • London Cancer Pathway board for lymphoma 2015
  • Invited speaker at UK Haematology Forum 2012 and 2014

News

  • April 2016: Reverse translation studies published in Blood and Molecular Therapy on preventing and understanding GvHD after allogeneic stem cell transplant
  • March 2015: Leukaemia & Lymphoma Research grant awarded to study GvHD in human gut
  • September 2014: Grants awarded for development of immune-modulation strategies post-transplant
  • August 2013: our study on bone marrow failure in AML featured by Science Daily and CRUK

See other researchers working on:

Blood cancers Clinical Trials Immunology Leukaemia Lymphoma
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.